LGDN:FRA
Ligand Pharmaceuticals
204,00ย โฌ
arrow_upward
+2,00%(+4,00) 1ะ
28 ะฐะฟั., 08:31:00 GMT+2 · EUR
search
ะัะต ัะธะผะฒะพะปั
1ะ
5ะะ
1ะะะก
6ะะะก
ะก1ะฏะ
1ะะะ
5ะะะข
ะะะะก
| ะกะธะผะฒะพะป | ะฆะตะฝะฐ | ะะทะผะตะฝะตะฝะธั | ะะธะฝะฐะผะธะบะฐ (%) |
|---|
insights_autoะกะพะทะดะฐะฝะธะต ััะฐัะธััะธะบะธ ะดะปั ัะธะบะตัะฐ LGDNโฆ
ะัะบัััั
204,00ย โฌ
ะััะพะบะฐั
204,00ย โฌ
ะะธะทะบะฐั
204,00ย โฌ
ะ ัะฝ. ะบะฐะฟ.
4,85ย ะผะปัะด
ะกัะตะดะฝ. ะพะฑัะตะผ
3,00
ะะฑัะตะผ
0,00
ะะฐะบั. ัะตะฝะฐ ะทะฐ 52 ะฝะตะด.
204,00ย โฌ
ะะธะฝ. ัะตะฝะฐ ะทะฐ 52 ะฝะตะด.
87,00ย โฌ
ะงะธัะปะพ ัะพัััะดะฝะธะบะพะฒ
47
ะะพะฒะพััะธ
ะะท ะธััะพัะฝะธะบะพะฒ ะฒ ะธะฝัะตัะฝะตัะต
Yahoo Finance
·
8 ัะฐัะพะฒ ะฝะฐะทะฐะด
Ligand Pharmaceuticals to Buy XOMA Royalty for $39/Share, Lifts 2026 Guidance and EPS Outlook
Investor's Business Daily
·
11 ัะฐัะพะฒ ะฝะฐะทะฐะด
Royalty Powerhouse: Ligand And Xoma Unite In $739 Million Deal
Quartz
·
17 ัะฐัะพะฒ ะฝะฐะทะฐะด
Ligand Pharmaceuticals is buying rival biotech royalty firm XOMA for $739 million
TipRanks
·
17 ัะฐัะพะฒ ะฝะฐะทะฐะด
Why Ligand Pharma Stock Is Suddenly Surging
ะัะพัะธะปั
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments.
Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
ะ ะบะพะผะฟะฐะฝะธะธ "Ligand Pharmaceuticals"
ะะตะฝะตัะฐะปัะฝัะน ะดะธัะตะบัะพั-
ะะพะปะธัะตััะฒะพ ัะพัััะดะฝะธะบะพะฒ47
ะะฐัะฐ ะพัะฝะพะฒะฐะฝะธััะตะฝั. 1987
ะจัะฐะฑ-ะบะฒะฐััะธัะฐะะถัะฟะธัะตั, ะคะปะพัะธะดะฐ, ะกะพะตะดะธะฝะตะฝะฝัะต ะจัะฐัั ะะผะตัะธะบะธ
ะกะตะบัะพั-
ะกะฐะนัligand.com
ะกะพะทะดะฐะฝะฝัะน ะะ ะบะพะฝัะตะฝั ะผะพะถะตั ัะพะดะตัะถะฐัั ะพัะธะฑะบะธ. ะะพะดัะพะฑะฝะตะตโฆ
ะกะฟัะฐะฒะบะฐะัะฟัะฐะฒะธัั ะพัะทัะฒะะพะฝัะธะดะตะฝัะธะฐะปัะฝะพัััะฃัะปะพะฒะธัะัะบะฐะท ะพั ะพะฑัะทะฐัะตะปัััะฒ